Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.460 +0.100 (+7.35%)
Streaming Delayed Price Updated: 11:53 AM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 930,948
Open 1.380
Bid (Size) 1.450 (1,300)
Ask (Size) 1.460 (1,400)
Prev. Close 1.360
Today's Range 1.350 - 1.510
52wk Range 0.8719 - 2.990
Shares Outstanding 35,631,576
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
From Biomea Fusion, Inc.
Via GlobeNewswire

Performance

YTD
+9.0%
+9.0%
1 Month
+5.0%
+5.0%
3 Month
-2.0%
-2.0%
6 Month
+17.7%
+17.7%
1 Year
-15.1%
-15.1%

More News

Read More
Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism ↗
Via Chartmill
Topics Earnings
News headline image
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib ↗
Via Benzinga
News headline image
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Upcoming Investor Conferences
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
Via Chartmill
News headline image
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Upcoming Investor Conferences
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Jefferies London Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
From Biomea Fusion, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Biomea Fusion, Inc. - Common Stock publicly traded?
Yes, Biomea Fusion, Inc. - Common Stock is publicly traded.
What exchange does Biomea Fusion, Inc. - Common Stock trade on?
Biomea Fusion, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Biomea Fusion, Inc. - Common Stock?
The ticker symbol for Biomea Fusion, Inc. - Common Stock is BMEA on the Nasdaq Stock Market
What is the current price of Biomea Fusion, Inc. - Common Stock?
The current price of Biomea Fusion, Inc. - Common Stock is 1.460
When was Biomea Fusion, Inc. - Common Stock last traded?
The last trade of Biomea Fusion, Inc. - Common Stock was at 07/02/26 11:53 AM ET
What is the market capitalization of Biomea Fusion, Inc. - Common Stock?
The market capitalization of Biomea Fusion, Inc. - Common Stock is 52.02M
How many shares of Biomea Fusion, Inc. - Common Stock are outstanding?
Biomea Fusion, Inc. - Common Stock has 52M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.